Videos

At the 2023 ASCO Annual Meeting, Helen Moon, MD, discusses results from a study investigating the real world response rates of patients with urothelial carcinoma treated with first-line platinum-based chemotherapy, to assess the uptake of...

Yutaka Yamamoto, MD, discusses OS results from the phase 3 PRECIOUS trial evaluating pertuzumab retreatment in patients with HER2-positive locally advanced or metastatic breast cancer.

Sara Tolaney shares the final overall survival analysis of the phase 3 TROPiCS-02 trial, evaluating sacituzumab govitecan in pretreated metastatic HR-positive breast cancer, which was presented at the 2023 ASCO Annual Meeting

At the 2023 American Society of Clinical Oncology Annual Meeting, Nirav Niranjan Shah, MD, shared findings from a phase 2 trial of split-dose R-CHOP for older patients with DLBCL.

At the 2023 ASCO Annual Meeting, Binod Dhakal, MD, presented phase 3 results from CARTITUDE-4 on the use of ciltacabtagene autoleucel therapy versus the standard of care therapy for patients with lenalidomide-refractory multiple myeloma.

Matthew Ballo, MD, discusses results from a meta-analysis of comparative studies showing a significant survival benefit with tumor treating fields therapy added to standard radiochemotherapy for patients with newly diagnosed glioblastoma.

At the 2023 ASCO Annual Meeting, Erika Hamilton, MD, discusses the antibody drug conjugate HER3-DXd, or patritumab deruxtecan.

At the 2023 ASCO Annual Meeting, Yael C Cohen, MD, presents results of the RedirecTT-1 study of the combination of teclistamab and talquetamab for the treatment of patients with R/R multiple myeloma.

Anna Minchom, MBBCh, MRCP, MD(Res), discusses updated safety results from the PALOMA trial and the identified recommended phase 2 dose for subcutaneous biweekly administration of amivantamab for patients with advanced solid malignancies.